OLMA
Olema Pharmaceuticals Inc
NASDAQ: OLMA · HEALTHCARE · BIOTECHNOLOGY
$7.49
+6.39% today
Updated 2026-10-28
Market cap
$601.11M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.12
Dividend yield
—
52W range
$6 – $36
Volume
1.2M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
3.7
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$36.50
+387.32%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy9 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.70 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-45.90M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-102.59M | $-96.66M | $-129.47M | $-162.45M | $-63.20M |
| EPS | — | — | — | — | $-2.12 |
| Free cash flow | $-82.43M | $-83.73M | $-104.51M | $-146.72M | $-45.90M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-01 | O'BYRNE, JASON | Buy | 650,000 | — |
| 2026-07-24 | HARMON, CYRUS | Sale | 12,500 | $11.71 |
| 2026-07-23 | HARMON, CYRUS | Sale | 12,500 | $11.58 |
Peer comparison
Smart narrative
Olema Pharmaceuticals Inc trades at $7.49. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 3.70, it sits in the safe zone.
Frequently asked questions
What is Olema Pharmaceuticals Inc's stock price?
Olema Pharmaceuticals Inc (OLMA) trades at $7.49.
Is Olema Pharmaceuticals Inc overvalued?
Olema Pharmaceuticals Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Olema Pharmaceuticals Inc (OLMA)?
The 12-month analyst consensus target is $36.50, about 387.3% above the current $7.49. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Olema Pharmaceuticals Inc's Altman Z-Score is 3.70, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-47.51%
Beta2.01
50D MA$9.82
200D MA$15.19
Shares out0.09B
Float0.06B
Short ratio—
Avg volume1.2M
Performance
1 week-8.69%
1 month-24.34%
3 months-43.03%
YTD-73.52%
1 year-24.69%
3 years—
5 years—